Company intelligence / Profile preview
AOBiome
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
AOBiome's lead candidate B244 demonstrated statistically significant improvement in atopic dermatitis (eczema) and pruritus (itch) in a large, placebo-controlled Phase 2b trial with a strong safety profile. B244 lowered itch and disease severity more than placebo and was well-tolerated, with plans for global Phase 3 trials underway.[7][5]
- Therapeutic areas
- ImmunologyEndocrinologyDermatologyCardiovascularNeurology
- Modalities
- Live biotherapeutic product therapyMicrobial therapyBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Biorasi (CRO partner for clinical trials)
Beyond the preview
Go deeper on AOBiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AOBiome.